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Editorial on the Research Topic
Phage Therapy: Past, Present and Future
INTRODUCTION
As an ancient proverb states, “The enemy of my enemy is my friend.” The so-called strictly lytic or
virulent bacteriophages (phages)—especially the viruses of pathogenic bacteria—can certainly be
considered enemies of “bad” bacteria and thereby our friends. The phage potential as antibacterial
agents was recognized almost immediately upon the first generally accepted descriptions of these
viruses as transmissible bacteriolytic entities (Abedon et al., 2011). As this was prior to Fleming’s
(1929) discovery of naturally occurring antibiotics, rather than being named as variations on that
theme, the Greek concept of “phage” was chosen instead (d’Hérelle, 1917). “Phage” seemingly is a
description of the macroscopic impact these viruses have on bacteria, which to the eye appear to be
“eaters” or “devourers” of bacterial cultures (Summers, 1991), in broth or solid media.
The therapeutic, antibacterial application of phages came to be known as phage therapy,
especially in clinical or veterinary contexts. More broadly, phages have also been used as biological
control agents, reducing bacterial loads in foods, e.g., such as of Listeria monocytogenes in food
processing (Bai et al., 2016), of zoonotic pathogens in food animals (Atterbury, 2009), or, in the
treatment of crops against plant pathogenic bacteria as reviewed by Buttimer et al. Furthermore,
modified phages can be used as DNA, protein, or drug delivery vehicles (Clark et al., 2012), and
non-bacterial viruses can be used as biological control agents as well (e.g., Hyman et al., 2013;
Kondo et al., 2013; Gilbert et al., 2015). Phage study, whether ultimately for therapy or biocontrol,
spans from purely clinical observation to molecular analysis to considerations of immunology
as well as ecology, the latter as phages represent essentially “living” drugs. In addition is the
development of enzybiotics, which are therapeutic enzymes and most prominently include phage
endolysins. The latter are proteins which phages employ to lyse the bacteria they are infecting,
thereby releasing intracellularly produced phage progeny (Fischetti, 2008).
This diversity of studies and approaches to antibacterial therapy is important since, despite∼100
years of phage and phage therapy study (Abedon et al., 2011), there is still much to learn about
phages and their use as therapeutic agents. There is also a compelling need for new safe and effective
selectively toxic antibacterials, especially in the face of the antibiotic resistance crisis (Aminov,
2010). Phages and their products thus represent a largely untapped supply of such antimicrobials.
Their use, however, has not yet been broadly embraced by the modern medical establishment.
Exceptions are found especially in the countries of Georgia, Poland, and Russia, where phage
therapy has been practiced by clinicians for many decades (Kutter et al., 2015; Cooper et al.).
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In this topic, we present 37 articles on or related to the
use of lytic phages as antibacterial agents. These are grouped
into several distinct categories, including (i) phage isolation for
phage therapy, (ii) host range characterization, (iii) other in
vitro phage characterizations, (iv) in vivo phage characterization,
(v) characterization of phage therapy in animals, (vi) phage
impact on bacterial biofilms, (vii) enzybiotics, (viii) clinical phage
therapy, (ix) biological control of bacteria using phages, and (x)
the current state of phage therapy implementation (Figure 1).
PHAGE ISOLATION FOR PHAGE THERAPY
Key to any successful drug development is its discovery and
subsequent characterization. For phage therapy, equivalent steps
should be taken, including determination of how to combine
FIGURE 1 | Topics addressed in this editorial. Connections are indicated via horizontal, vertical, and diagonal lines, and initial steps are found at the top of the figure.
Consideration of time and resources required by each step is beyond the scope of this editorial, though individual aspects are considered in articles as cited in the
main text. In summary, phage isolation is typically done in combination with preliminary host-range characterization, i.e., as in terms of enrichment and isolation hosts.
This is followed by in vitro characterization in association with further host-range characterization (i.e., involving a larger panel of potential hosts) and bioinformatic (in
silico) characterization. Enzybiotic development, if undertaken, typically will follow host-range and in silico characterization. For promising phages, in situ
characterization comes next, including animal models for potential human treatments (in vivo characterization), or with other species for non-human treatments.
Clinical testing can follow, including treatment of non-human species. Alternatively, phages may be employed for biological control of environments, and both
biological control and therapeutic use of phages can be against biofilms. Not only may whole phages be used for therapy or control but so too may enzybiotics.
Further development toward successful commercial or public-sector implementation generally must address regulatory requirements.
phages into multi-phage mixtures known as phage cocktails. The
review article in this topic by Weber-Da˛browska et al. discusses
the essential steps involved including sources and methods of
phage isolation, choice of phage-propagation hosts, methods of
characterization, selection criteria for therapeutic purposes, and
limitations on phage procurement for therapy.
The use of phages as antibacterial therapeutics is especially
important for targeting those pathogens for which antibiotic
treatment options are limited. On-demand isolation of
corresponding phages can be achieved via the enrichment
of samples from environmental reservoirs, as explored by
Mattila et al. Interestingly, the efficiency of enrichment-based
phage isolation from municipal sewage varies considerably, with
the best results seen for Pseudomonas aeruginosa, Salmonella,
and the extended spectrum β-lactamase (ESBL) producing
Frontiers in Microbiology | www.frontiersin.org 2 June 2017 | Volume 8 | Article 981
Abedon et al. Editorial: Phage Therapy
Escherichia coli and Klebsiella pneumoniae. The procedure
is less efficient for vancomycin-resistant Enterococcus and
Acinetobacter baumannii, while isolation of new phages against
methicillin-resistant Staphylococcus aureus (MRSA) strains was
very difficult. Potentially, the latter may be due to the choice of
environmental reservoir used for the anti-MRSA phage isolation
since, as Wang et al. show, pig fecal sewage may be a better
source for these phages.
HOST RANGE CHARACTERIZATION
Prior to animal testing there are various approaches
toward characterizing phages for antibacterial effectiveness
(Weber-Da˛browska et al.). Most important is the range of
bacteria targeted (Mirzaei and Nilsson, 2015). As a minimal
requirement for phage therapy, a phage should be able to infect
the bacterial isolates it is supposed to be targeting, and to
display reasonable specificity so that non-target bacteria are not
affected. A proper understanding of phage host range is also
necessary for the development of efficient cocktails, which ideally
would be formed using multiple phages that possess synergistic
properties, particularly in terms of host range, thereby offering
better infection control capability. Nevertheless, for some phage
applications such as phage therapy and phage-based biosensors,
it should be taken into account that host range is not a fixed
property, but rather it can evolve over time, thereby changing
phage specificity (Ross et al., 2016).
For obvious reasons, multidrug-resistant (MDR) pathogens
are a primary target for phage therapy. The host range of four
phage cocktails that are approved and commercially available
in Georgia have been tested by Gundogdu et al. on a panel of
142 clinical strains of E. coli isolated in Turkey and possessing
extended-spectrum β-lactamase activity. The phage cocktail
antibacterial efficiencies varied from 59.2 to 87.3% of strains, as
based on spot testing, which is promising given that these were
difficult-to-treat MDR bacterial strains.
In addition, and like antibiotic therapy, phage therapy can
result in the evolution of bacterial resistance. Understanding
resistance development is important in terms of both basic
biology and phage-based applications. Some phage resistant
bacteria are less fit than their phage-sensitive parents. Lim et al.
found that phage PB1-resistant P. aeruginosa displayed small-
colony variants which were impaired in biofilm formation, were
more antibiotic sensitive, displayed decreased twitching motility,
and had reduced elastase and pyocyanin production.
OTHER IN VITRO PHAGE
CHARACTERIZATIONS
In addition to the assessment of host range (previous section),
other phage “organismal” characteristics such as burst size, ability
to display lysogeny, and general plaque morphology should
be evaluated. In vitro characteristics also include the ability
to degrade experimental bacterial biofilms (subsequent section)
along with complete genome sequencing. The latter typically
is followed by in silico analyses, especially to exclude phages
carrying bacterial virulence factor genes. Also, it is advantageous
to exclude phages carrying lysogeny-associated genes. Hamdi
et al. isolated five phages that infect Citrobacter freundii which
they found had no known virulence factor or integrase genes.
The latter are employed by many phages to initiate lysogenic
cycles. Such properties suggest potential utility for these phages
as antimicrobial agents.
Bardina et al. isolated and characterized three phages
(UAB_Phi20, UAB_Phi78, and UAB_Phi87) infecting Salmonella
to reduce the presence of this zoonotic bacterium in poultry.
Sequence analysis of genomes did not indicate the presence
of virulence factor or antibiotic resistance genes. Phage
UAB_Phi20, however, encodes lysogeny-associated genes,
although no lysogens could be isolated. The authors suggest that
this could be because of a lack of signals needed to transcribe the
CI repressor gene required for establishment of lysogeny.
Lytic phage development also depends on the physiological
state of the host. According to Bryan et al. T4 phages infecting
stationary phase E. coli may enter a “hibernation” mode,
which is a persistent but reversible dormant state. Infected
bacteria continue to produce some phage proteins, but phage
development is halted until appropriate nutrients become
available. A “scavenger” mode is encountered when exposed
to limited nutrients, with the production of small quantities
of progeny per infection. These considerations are important
in understanding phage therapy of bacteria displaying varied
physiological states, such as within biofilms or during chronic
bacterial infections.
IN VIVO PHAGE CHARACTERIZATION
By in vivo we mean in situ phage assessment within other
organisms or surrogates, such as during animal testing
(further considered in a subsequent section). Such assessment
includes in terms of safety to the host during treatment,
though in practice few side effects with phage therapy have
been detected (Miedzybrodzki et al.). Potential cytotoxic
effects can also be evaluated using eukaryotic cell lines via
different assays such as trypan blue, staining with Hoechst and
propidium iodide, lactate dehydrogenase release, and the MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) assay, as described in this topic
by Henein et al.
Important as well are phage and especially virion interactions
with immune systems, which is a concern for biologics generally,
i.e., protein-based drugs. In the article by Mirzaei et al. several E.
coli phage preparations, were found to induce strong cytokine-
driven inflammatory responses in HT-29 and Caco-2 intestinal
epithelial cells. Whether this was the effect of phages per se or
residual contaminants in phage preparation(s) was questioned by
Dufour et al., however. As a Response, Mirzaei et al. proposed
morphological differences as possible bases of contradictory
outcomes, perhaps highlighting a need for better standardization
of approaches. Mirzaei et al., in a subsequent Corrigendum,
acknowledged that at least some aspect of the cytokine responses
described in the original publication may have been due to
residual contaminants.
Frontiers in Microbiology | www.frontiersin.org 3 June 2017 | Volume 8 | Article 981
Abedon et al. Editorial: Phage Therapy
For lipopolysaccharide (LPS)-activated monocytes, neither
purified phage T4 nor T4 lysate, according to the results of Bocian
et al., had a significant impact on the ex vivo human immune
response. Phage lysates however, may affect the differentiation
of human monocytes into myeloid dendritic cells, but purified
phage preparations do not have that effect (Bocian et al.). Also
regarding LPS, Miernikiewicz et al. found that recombinant
short tail fiber (gp12) from phage T4 decreased inflammatory
responses to LPS in a murine model. Cell culture and mouse
testing indicated no toxicity, suggesting that this recombinant
protein potentially could be used as an anti-LPS medicinal.
No significant increase in antiphage antibodies in the sera
of most patients undergoing anti-staphylococcal phage therapy
were detected by Z˙aczek et al. In patients with the increased
titers of antiphage IgG and IgM to these phages, no interference
with phage therapy clinical outcomes were observed. While the
influence of purified T4 and A3/R phages on differentiation
of human myeloid dendritic cells (DCs) from monocytes is
negligible, phage-lysed bacterial material has a substantial effect
on their differentiation (Bocian et al.). Thus, the products of
phage-induced lysis of bacteria during phage therapy could
influence the differentiation as well as potentially the functions




In the modern era, clinical use of drugs typically is preceded by
animal testing. Phage therapy, since it has been in practice for so
long, comes from a tradition where clinical use has tended to take
precedence over animal testing (Abedon, 2015c). Phage therapy
in the modern era nonetheless has to adopt current standards of
drug development, that is, in which animal testing by necessity
precedes clinical use, and several articles in the topic are devoted
to animal testing of phages and phage preparations.
Wang et al. characterized the staphylococcal phage SLPW.
Treatment of intra-abdominal MRSA infections in mice with
phage SLPW provided high protection (80% survival) as well
as reduction of infection-induced inflammatory cytokines, thus
substantiating this phage as a potential therapeutic agent against
MRSA infections. With a Clostridium difficile target, a 4-phage
cocktail was tested in a Galleria mellonella larva model and
was found by Nale et al. to be as effective as vancomycin.
Another problematic multi-drug resistant nosocomial pathogen,
A. baumannii, was targeted using phage vB-GEC_Ab-M-G7 by
Kusradze et al. In a rat wound model, this phage substantially
decreased bacterial loads.
Abedon briefly reviewed in a general commentary a rabbit
staphylococcus osteomyelitis model system published by Kishor
et al. (2016). Presented as well is a summary of several
animal presumptive chronic infection models previously used for
phage therapy development. A series of criteria are suggested
for confirmation that such systems represent adequate disease
models including demonstration of antibiotic tolerance by
infecting bacteria and/or of presence of biofilms.
Pharmacological issues of phage therapy include phage
transit from the stomach to the distal gastrointestinal tract.
Mie˛dzybrodzki et al. showed in a rat model that modification
of the stomach environment using the drugs ranitidine and
omeprazole, which reduce production of stomach acid, protect
staphylococcal phage A5/80, allowing passage to the lower
intestine. These authors also found that phage penetration from
oral administration to systemic circulation can differ among
phage types as phage A5/80 reaches the bloodstream following
oral administration aided by acid-reducing drugs but similarly
administered T4 did not.
PHAGE IMPACT ON BACTERIAL BIOFILMS
Formation of biofilms during bacterial infection is one of
the major problems in infection control. Bacteria in biofilms
are extremely resistant to antimicrobials, well protected from
host defenses, and tend to develop chronic infections (Cooper
et al., 2014). Some bacteriophages penetrate biofilms and this
may supplement or replace a less efficient antibiotic treatment
(Abedon, 2015a,b). C. difficile, for example, produces biofilms
which contribute to its virulence and impair antimicrobial
activity. Nale et al. found that a cocktail ofC. difficile phages could
significantly reduce these biofilms and prevent colonization when
used either alone or in combination with vancomycin.
Catheter-associated urinary tract infections (CAUTIs) such
as caused by Proteus mirabilis are very difficult to treat as they
form biofilms that are highly tolerant to antibacterials. Two
novel virulent phages active against P. mirabilis were isolated,
characterized, and studied for application on catheter-associated
biofilms by Melo et al. In a dynamic biofilm model simulating
CAUTIs, the authors demonstrated a significantly lower rate of P.
mirabilis biofilm formation up to 168 h following catheterization,
thus highlighting the potential of these phages in preventing
bacterial surface colonization.
Biofilms can also be targeted by degrading the matrix in
which bacterial cells are suspended. Gutiérrez et al. tested a
recombinant protein from a staphylococcal phage encoding
an exopolysaccharide depolymerase, a kind of enzybiotic.
In polysaccharide producing staphylococci the enzyme can
prevent and disperse biofilms, thus potentially allowing better
antimicrobial access to targeted bacteria.
ENZYBIOTICS
Purified antibacterial enzymes have been described as enzybiotics
(Veiga-Crespo et al., 2007), i.e., as derived from ‘antibiotic’.
These can include extracellular polymeric substance (EPS)
depolymerases (as above) but also, phage-encoded lytic enzymes,
i.e., lysins. Though some lysins are virion-particle associated, as
are many EPS depolymerases (Pires et al., 2016), the majority are
endolysins, meaning “from-within cell-wall degrading enzymes.”
Enzybiotics upon purification, however, are applied from
without.
The peptidoglycan of Gram-positive bacteria is not protected
by an outer membrane so is directly susceptible to phage lysins
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applied from without. Blazquez et al. generated a novel (“tailor-
made”) endolysin (PL3) targeting Streptococcus pneumoniae.
It combines the amidase activity of a phage endolysin (Pal)
with that of LytA, a Streptococcus autolysin. Joining these two
unrelated catalytic domains into a single protein resulted in
greater antibacterial activity in a zebrafish model.
In Gram-negative bacteria, phage lysins typically need to
be modified to penetrate the outer membrane barrier. This
can be done by engineering hybrid molecules that combine
natural lysin with an antimicrobial peptide. Yang et al. found
that one such construct, PlyA, displayed good activity against
growing cultures of bothA. baumannii and P. aeruginosa, but not
against stationary phase cells unless used with outer membrane
permeabilizing agents. No antibacterial activity, however, could
be detected in some bio-matrices such as culture media, milk,
or sera, suggesting a need for further optimization. Endolysins
such as ABgp46, as characterized by Oliveira et al., are also active
against A. baumannii, including MDR strains. In addition, the
range of activity of this lysin can be extended to other Gram-
negative bacteria if used in combination with outer membrane
permeabilizing agents. Endolysin LysABP-01 from A. baumannii
phage ØABP-01 also possesses antibacterial activity against A.
baumannii and P. aeruginosa as well as E. coli, which as shown
by Thummeepak et al. can be enhanced in the presence of the
antibiotic colistin.
CLINICAL PHAGE THERAPY
Clinical phage therapy is the treatment or prevention of
infections in humans and the use of phages in microbiome
modification. In addition is the related use of phages to treat or
prevent infections in animals. Clinical phage therapy is permitted
for routine use in a limited number of countries though the
corresponding data from these efforts is limited. Because of the
long-term treatment requirements of chronic conditions such as
cystic fibrosis, the appearance of bacterial resistance to phages
can be a problem. Krylov et al. propose to employ a combinatorial
approach during treatment of drug-resistant P. aeruginosa to
circumvent this problem, by using phages with a proven safety
record combined into cocktails.
Although not life-threatening, some chronic skin infections,
such as caused by Propionibacterium acnes, can require long-
term antibiotic treatment, thus contributing to dysbiotic changes
in microbiomes and selection for antimicrobial resistance. Phage
therapy of acne may be a valuable alternative to reduce the
overuse of antibiotics in the treatment of this condition, as
reviewed by Jonczyk-Matysiak et al.
BIOLOGICAL CONTROL OF BACTERIA
USING PHAGES
In the review article by Buttimer et al., phage biocontrol of
bacterial crop diseases is compared to chemical control measures.
Phages they suggest are more environmentally friendly, can be
tailored against specific disease-causing bacteria, and can be
easily reformulated if resistance develops. Some field trials, for
example, have shown potential for phage biocontrol of bacterial
blight of leek, as explored by Rombouts et al.
Another aspect of biocontrol (vs. phage therapy in the strictest
sense) is reduction of loads in animals of what otherwise could
be food-borne pathogens. In poultry, Ahmadi et al. found that
the prophylactic administration of phage PSE, active against
Salmonella enterica serovar Enteritidis, significantly reduced
shedding of this pathogen. Improved biocontrol measures against
Salmonella will include the selection of phages that can infect
a broader range of bacterial strains. This has been explored,
including in terms of phage genomics, by Bardina et al.
In another example of biocontrol, Hernández reported that
bacteriophages against Serratia spp., which can spoil Atlantic
horse mackerel (Trachurus trachurus), were isolated and tested
for protection of fresh filets. Reductions in Serratia counts of
more than 90%were observed in treatment with about 108 phages
per gram of filet after 6 days of refrigerated storage (6◦C). Phage
application at lower densities was less effective.
THE CURRENT STATE OF PHAGE
THERAPY IMPLEMENTATION
An important aspect of drug utility is availability, and this
requires adequate manufacturing, marketing, and delivery to as
well as education of users. Prior to these steps, it is necessary
to maintain an adequately robust development pipeline along
with strategies toward regulatory approval. Presently, phage
therapy is relatively extensively used only in three countries,
Georgia, Poland, and Russia, while its acceptance and re-
implementation in other countries is still pending (Expert Round
Table on Acceptance and Re-Implementation of Bacteriophage
Therapy, 2016). As discussed by Cooper et al., difficulties
with acceptance are due to: (i) differences in biological,
physical, and pharmacological properties of phages compared
to conventional antimicrobials, (ii) the need to employ multiple
phage isolates (cocktails) due to the high specificity of phages
(thereby allowing for more effective presumptive treatment,
that is, treatment which is initiated prior to precise diagnosis
of microbial etiologies), and (iii) current approval processes
for antimicrobial agents that are based on chemically derived
drugs and which consequently are less suitable for phages.
Alternative approval pathwaysmay be required for phage therapy
(Aminov et al., 2017), while phage-derived enzybiotics are
already suitable for the current approval processes as therapeutic
proteins.
Based on the wealth of data obtained by some phage therapy
centers, Górski et al. suggest that it is time to consider phage
therapy benefits in their entirety, including compassionate use
targeting cohorts of patients for whom no alternative treatment
is currently available. The effects of phage therapy, which target
infectious agents and which also can modulate the immune
system, resemble the effect of antibiotics, which, in addition to
antibacterial activity, can display other regulatory effects on the
human body (Aminov, 2013). Thus, the impact of phages beyond
intended antibacterial activity should be carefully evaluated
in association with more standard practices of phage therapy
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development. Lastly, Nagel et al. point out that as infectious
diseases significantly affect developing countries, phage therapy
considering its relative technical simplicity as well as ease
of phage isolation, characterization, and production, could be
especially useful in these settings.
CONCLUSION
Bacteriophages have been instrumental in the development of
modern biology, particularly the understanding of biological
process at the molecular level which has been crucial for the
development of modern biological sciences (Cairns et al., 1966;
Summers, 1999). They have also been used therapeutically
for ∼100 years, with a good safety record (although their
exploitation in this regard has lagged behind their use in
molecular biology). Publications demonstrating the safety of
phage applications (some of which include phase I safety trials)
include (Rhoads et al., 2009; Wright et al., 2009; Miedzybrodzki
et al., 2012; Sarker et al., 2012, 2016; Rose et al., 2014; Fish
et al., 2016; Speck and Smithyman, 2016). Nonetheless, and
despite a demonstrated need for new, safe antibacterial agents
(Aminov, 2016), phage use by most Western physicians has
not yet caught on, and this is due (presumably) to a lack of
familiarity with phage therapy, but also because of a relative
lack of regulatory approval. This volume provides an overview
of a substantial number of facets of use of phages and their
products in a medical and especially antibacterial context. We
believe, in the face of the looming antibiotic crisis, that this
approach deserves serious consideration. Hopefully phages can
prove as revolutionary in the medical field as they have in the
scientific.
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